Insurance broker Arthur J. Gallagher raises its quarterly dividend, rewarding shareholders even as it continues to pursue an active mergers and acquisitions pipeline, signaling confidence in its dual strategy of capital returns and growth.
With its share price up nearly 40% in a month, Bannerman Energy (ASX:BMN) is drawing intense investor scrutiny ahead of its December quarter report and investor webinar. Analysts weigh whether the uranium developer's rally has outpaced fundamentals.
The ASX-listed miner's heavily discounted rights issue aims to shore up its balance sheet after a period of steep losses, but analysts are divided on whether the fresh capital marks a new beginning or merely delays deeper challenges.
Fresh from its spin-off, GE Vernova is finalizing a deal to acquire transformer maker Prolec GE, a strategic move to bolster its electrification portfolio and capitalize on surging global demand for grid infrastructure and power equipment.
CNBC's Jim Cramer suggests Intel shares could surge significantly, as the chipmaker's strategic overhaul and analyst upgrades fuel investor optimism amid a 140% yearly gain.
In a bid to attract new entrants to the market, financial services firm SoFi is offering a significant stock bonus of up to $1,000 for opening a self-directed investment account, eliminating traditional barriers like commissions and minimums.
The Australian chemicals company SciDev (ASX:SDV) is showing early signs of a financial transformation, with its return on capital employed turning positive after years of losses. While its current returns still lag the industry average, a significant increase in capital deployment suggests the firm is aggressively reinvesting for growth.
USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.
As the Bank of England prepares for a leadership transition in 2028, a debate ignited by former Fed governor Kevin Warsh gains traction: should central banks shed ancillary roles and return to their core mission of price stability?
Sugar futures tumbled further this week, with New York prices hitting a 2.5-month low and London white sugar sinking to a five-year trough, as analysts warn of swelling global surpluses driven by record harvests in Brazil and India.
Anthropic's viral 'vibe coding' tool, Claude Code, is rapidly altering software development practices across North Carolina's tech sector, prompting strategic pivots, stock market jitters, and a fundamental rethink of the human role in the process.
Amid a broader leadership restructuring, financial giant Charles Schwab has appointed its CIO, Dennis Howard, to lead a consolidated unit overseeing technology, operations, and data, signaling a strategic shift to deepen the integration of IT with core business functions.
Analyst firm Clear Street has raised its price target for Critical Metals Corp. (CRML) to $20, citing a strategic joint venture with a Saudi industrial group to build a rare earth processing facility. The move aims to diversify supply chains away from China and support Western defense needs.
Despite a trimmed price target from B. Riley, WhiteFiber Inc. (WYFI) secures a pivotal 10-year colocation agreement expected to generate $865 million, spotlighting its role in the expanding AI infrastructure sector.
Deutsche Bank has upgraded AI infrastructure provider CoreWeave to 'Buy,' significantly raising its price target to $140, citing a strong medium-term outlook and capacity expansion plans backed by a deepened partnership with Nvidia.
Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Analysts remain divided on Gogo Inc.'s trajectory as the in-flight connectivity provider navigates its 5G network launch against a backdrop of strategic shifts and evolving satellite technology debates.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
